Cardiovascular

FDA allows marketing of first system to repair failed or problematic aortic endografts

The U.S. Food and Drug Administration is allowing marketing of the first system—a minimally invasive option—that can repair a failed or problematic aortic endograft. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares